The COVID-19 pandemic has presented unprecedented challenges around the world, including to national public health systems and the international biopharmaceutical industry.
The opioid crisis in the U.S. seems to be part of nearly every news broadcast and news site today. And based on the number of people affected by this crisis, serious conversations about how to help are more important than ever.
USP is exploring how its extensive expertise in developing quality standards for drug products and ingredients can contribute to pharmaceutical continuous manufacturing.
Comment on USP's proposed Drug Classification System by December 5, 2016.